Journal
BREAST CANCER RESEARCH
Volume 8, Issue 6, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/bcr1612
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [P30CA016672, K01CA118174] Funding Source: NIH RePORTER
- NCI NIH HHS [CA-16672, K01CA118174, K01 CA118174, P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. The majority of patients with metastatic breast cancer who initially respond to trastuzumab develop resistance within one year of treatment initiation, and in the adjuvant setting 15% of patients still relapse despite trastuzumab-based therapy. In this review, we discuss potential mechanisms of antitumor activity by trastuzumab, and how these mechanisms become altered to promote therapeutic resistance. We also discuss novel therapies that may improve the efficacy of trastuzumab, and that offer hope that the survival of breast cancer patients with HER2-overexpressing tumors can be vastly improved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available